Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibodies as cytotoxic therapy

R O Dillman1

  • 1Hoag Cancer Center, Newport Beach, CA 92663.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|July 1, 1994
PubMed
Summary

Unconjugated monoclonal antibodies show limited therapeutic benefit in cancer trials so far. Research is ongoing, focusing on humanized antibodies and those targeting growth factor receptors for future cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous peripheral blood mononuclear cell recognition of autologous proliferating tumor cells in the context of a patient-specific vaccine trial.

Journal of biomedicine & biotechnology·2011
Same author

Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival.

Cancer immunology, immunotherapy : CII·2010
Same author

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.

Clinical and experimental medicine·2006
Same author

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

How can we improve survival rate for patients with non-small-cell lung cancer?

Clinical lung cancer·2004
Same author

Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2003

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibodies (mAbs) are increasingly explored for cancer therapy.
  • Unconjugated mAbs offer a targeted approach without drug or toxin conjugation.

Purpose of the Study:

  • To review clinical trials of unconjugated monoclonal antibodies in cancer treatment.
  • To identify promising antibody targets and assess current therapeutic benefits.

Main Methods:

  • Systematic English-language literature search for clinical trials.
  • Focus on unconjugated monoclonal antibodies in cancer patients.

Main Results:

  • Most trials were early-phase (pilot, Phase I-II).
  • Encouraging results seen for antibodies targeting lymphoma, melanoma, sarcoma, and neuroblastoma.
  • Low toxicity observed, but anti-murine antibody responses limited efficacy.

Conclusions:

  • Currently, no unconjugated mAbs demonstrate proven therapeutic benefit for hematologic malignancies or solid tumors.
  • Future research focuses on antibodies targeting growth factor receptors and humanized antibody development.

Related Experiment Videos